New study shows blood test detected cancer metastasis

September 30, 2013, Chronix Biomedical

Researchers from the University Göttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer. Appearing in the peer-reviewed journal PLOS ONE, the paper identifies important similarities and differences between human and canine breast tumors, providing a strong platform for future research using the canine model system.

As part of the project, the research team successfully implemented Chronix Biomedical's innovative protocol for detecting tumor DNA found in the cell-free portion of blood, and thus demonstrating the power of this application for monitoring minimal residual disease in . The data generated provides a personalized readout of cancer genotype in each individual patient and can be used to track disease progression both pre- and post-treatment.

Tracking cancer status

The research team analyzed five canine mammary carcinomas in the study. Each was shown to exhibit gross chromosome instability, similar to those observed in human samples. These variations included chromosomal and segmental copy-number changes in several well-described cancer genes, such as cMYC, MYB, CFA1, and HER2/ERBB2. However, a recurrent deletion of the proximal part of chromosome 27 that contains the tumor suppressor gene PFDN5, which is so far not described as recurrently deleted in human breast cancer, also had been detected. The researchers found the deletion in 50 percent of the 20 canine carcinomas that were analyzed.

Perhaps most remarkable, the researchers were able to use cell-free DNA (cfDNA) analyses to detect and measure the occurrence of specific chromosomal breakpoints in blood plasma. The first step of the process involves massively parallel sequencing to detect unusual chromosome rearrangements, the likes of which are the hallmark of cancer cells. These can then be reliably detected and quantified subsequently using highly sensitive digital PCR. The combined approach is a very cost-effective option for tracking tumor progression or recurrence.

Dr. Julia Beck, Senior Scientist at Chronix Biomedical and first author of the study, commented: "We were able to detect the persistence of a plasma tumor marker after surgery in one of the canine patients, directing veterinarians to schedule a tomographic examination that revealed metastatic lesions in the lung. We're confident that the same approach could be reliably used to analyze human blood samples."

Prof. Dr. Bertram Brenig, director of the Institute of Veterinary Medicine at the University of Göttingen and co-author of the study, feels confident that the results of the study will have remarkable impact on the future decisions regarding the therapy of mammary tumors in dogs. Commenting, he said, "This minimally invasive diagnostic tool offers the great opportunity to identify potential tumor development in at-risk patients at an early stage and follow up the progress after surgery."

Extending the cfDNA approach to human cancer

Although cancer treatments have improved significantly over the last few decades, several hurdles remain to be overcome. Currently, no methods can accurately differentiate between those patients exhibiting a significant response to treatment and those still harboring residual . This means that further treatments must be routinely performed on all patients, often unnecessarily.

To improve the effectiveness of cancer treatment and minimize patient suffering, Chronix Biomedical is already extending its studies using cfDNA to assessing tumor status in human samples. Chronix Biomedical has developed a cfDNA blood test to monitor minimal residual disease in most cancers that will enable physicians to make informed treatment decisions based on both the unique genetic makeup of each patient's tumor, and the likelihood that the tumor is still present after therapy.

Chronix Biomedical's Chief Technology Officer and senior author of the study, Ekkehard Schütz, M.D., Ph.D., is confident that the approach has great potential for providing quantitative data on tumor incidence, without the need for invasive biopsies. Commenting on the study, Dr. Schütz said: "Our results so far indicate that cfDNA can provide a powerful means of assessing status as a 'liquid biopsy', both at the earliest stages of cancer development and following treatment or surgery. Such diagnostic information could be a powerful means of improving treatment outcome."

"We have already seen some very positive results using our blood tests," said Howard Urnovitz, Ph.D., CEO of Chronix Biomedical, whose team recently collaborated with The University of Texas MD Anderson Cancer Center to present preliminary data from their research at the American Society of Clinical Oncology Annual Meeting 2013. "By providing a means of tracking the body's response to treatment, we expect these tests to enhance patient care, while also greatly reducing the cost to the healthcare system."

Explore further: Enhanced luminal breast tumor response to antiestrogen therapy

More information: dx.plos.org/10.1371/journal.pone.0075485

Related Stories

Enhanced luminal breast tumor response to antiestrogen therapy

September 3, 2013
Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment ...

Scientists pair blood test and gene sequencing to detect cancer

November 28, 2012
Scientists at the Johns Hopkins Kimmel Cancer Center have combined the ability to detect cancer DNA in the blood with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients ...

Major cancer genotyping study logs 5,000th tumor profile

September 12, 2013
More than 5,000 genetic profiles of tumor DNA have been completed in a large research study by scientists at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital designed to speed the ...

Scientists identify targets for melanoma immunotherapy

September 10, 2013
Using a highly sensitive technology called NanoString, researchers have identified seven targets that could potentially be used to develop new immunotherapies for patients with metastatic melanoma, according to a study published ...

Protein protects against breast cancer recurrence in animal model

June 13, 2013
According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence – the reappearance ...

New approach to treating human brain cancer could lead to improved outcomes

September 25, 2013
A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham). The method targets cancer stem cells—the ...

Recommended for you

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.